By Marta Falconi
ZURICH--A Geneva hospital said Monday it was resuming tests of
an experimental Ebola vaccine licensed by Merck & Co. after a
three-week pause in the trial to assess reports of mild joint pain
in volunteers.
In a statement, the University Hospitals of Geneva said a second
test group of 56 people will receive injections of the vaccine,
which is known by the code name VSV-ZEBOV, at a lower dose than the
initial group of volunteers. The test, which is being conducted on
healthy volunteers, will continue through the end of the month with
final results expected in March.
The study team suspended the Geneva trial on Dec. 11 as a
precaution following reports of mild joint pain in some test
subjects. On Monday, the hospital said 10 of the initial 59
volunteers reported joint inflammations roughly two weeks after
receiving the injection.
The symptoms disappeared without treatment, the hospital
said.
The study team is lowering the dosage to 300,000 vaccine
particles for the second group of volunteers, instead of 10 million
or 50 million particles that were used in the first part of the
study. The hospital said the lower dosage should be better
tolerated by the trial participants but still trigger the
production of enough antibodies needed to fend off the Ebola
virus.
Merck said in an email that they were aware of the trial's
resumption and looked forward to final results of the study.
In November, Merck, based in Whitehouse Station, N.J., agreed to
pay NewLink Genetics Corp. of Ames, Iowa, $30 million for the
rights to the vaccine. Merck will also pay an additional $20
million and royalties on sales if the vaccine meets certain
development targets.
Ebola has claimed over 7,900 lives in Guinea, Liberia and Sierra
Leone, where the current outbreak is concentrated, according to the
World Health Organization. A total of 20,381 confirmed, suspected
or probable cases of Ebola cases have been recorded so far in the
three countries.
The disease spreads via bodily fluids and causes high fever and
internal bleeding. Currently no vaccines are available to protect
against Ebola.
Write to Marta Falconi at marta.falconi@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires